INOVIO Pharmaceuticals, Inc. — 2019 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019. The filing is an annual report, not a standalone fourth-quarter filing; it also provides unaudited quarterly results. Inovio is a clinical-stage biotechnology company developing DNA vaccines, immunotherapies and DNA-encoded monoclonal antibodies, delivered using its CELLECTRA devices. It reported no product sales, and none of its product candidates had received marketing approval.
Financial performance and position
| Metric | 2019 | 2018 |
|---|---|---|
| Total revenue | $4.1 million | $30.5 million |
| Research and development expense | $88.0 million | $95.3 million |
| General and administrative expense | $27.2 million | $29.3 million |
| Operating loss | $111.1 million | $94.1 million |
| Net loss attributable to Inovio | $119.4 million | $97.0 million |
| Basic and diluted loss per share | $1.21 | $1.05 |
| Cash and cash equivalents | $22.2 million | $23.7 million |
| Short-term investments | $67.3 million | $57.5 million |
| Working capital | $62.2 million | $52.5 million |
| Total assets | $144.0 million | $131.1 million |
| Total liabilities | $138.5 million | $44.1 million |
| Total stockholders’ equity | $5.4 million | $87.0 million |
- Cash flow: Cash used in operating activities was $97.9 million, compared with $73.6 million in 2018. Investing activities used $9.0 million; financing activities provided $105.4 million. Year-end cash and cash equivalents declined by $1.5 million.
- Revenue and concentration: Revenue fell 87%, primarily because 2018 included a one-time $23.0 million ApolloBio upfront payment. In 2019, AstraZeneca contributed $3.2 million, or 78% of total revenue. Grant funding is generally recorded as a reduction of R&D expense, not revenue; $11.9 million of such contributions reduced 2019 R&D expense.
- Debt and liquidity: In 2019, Inovio issued $78.5 million principal of 6.5% convertible senior notes and convertible bonds with approximately $19.1 million principal denominated in Korean won. Their year-end carrying amounts were $64.2 million and $12.8 million, respectively; a separate $8.8 million derivative liability related to the August bonds. The bonds have conversion and repurchase provisions, and the August bonds’ disclosed effective interest rate was 29.4%, despite a 1% coupon. Contractual payments on the convertible debt, including stated interest and premiums, totaled approximately $127.5 million.
- Management said year-end cash and short-term investments were sufficient for planned working capital needs for at least 12 months. Separately, through March 11, 2020, the company sold 43.1 million additional shares under its amended ATM program for $208.2 million net proceeds; the ATM capacity was then exhausted. Those subsequent proceeds materially changed liquidity and share count after year-end.
- Margins/profitability: The filing reports operating and net losses and no product revenue; positive product gross margins are therefore not applicable. The company had an accumulated deficit of $739.8 million and expected substantial future operating losses.
Material changes and quarterly results
- Fourth-quarter 2019 revenue was $279,000 and net loss attributable to Inovio was $37.7 million, versus revenue of $2.5 million and net loss of $33.0 million in fourth-quarter 2018. Q4 2019 operating loss was $30.4 million. The quarter included a $4.3 million unfavorable change in fair value of the derivative liability; annual derivative fair-value expense was $1.8 million.
- Annual operating loss increased by $17.0 million, while net loss attributable to Inovio increased by $22.4 million. Lower R&D and G&A expenses did not offset the sharp revenue decline and increased interest and other financing-related expenses.
- In July 2019, Inovio reduced its workforce by approximately 28%, discontinued its Phase 1/2 advanced bladder-cancer trial of INO-5401, and recorded a $2.2 million restructuring charge. It reported year-end equity of only $5.4 million, alongside the new debt and derivative liabilities.
Outlook, commentary and principal risks
- Pipeline and development: VGX-3100 Phase 3 REVEAL 1 enrollment was completed in June 2019; enrollment in the parallel REVEAL 2 study was ongoing. AstraZeneca funded MEDI0457 development. Interim results from a 52-patient GBM study reported six-month progression-free survival in 80% of MGMT-methylated and 75% of unmethylated patients; these were interim, non-final results, not proof of approval or commercial efficacy.
- COVID-19 program and forward-looking targets: In January 2020, CEPI awarded up to $9 million for development of INO-4800. As of the filing, Inovio expected to seek U.S. Phase 1 trial commencement in April 2020, subject to FDA authorization, and stated a goal of producing up to one million doses by year-end 2020 for further trials or emergency use. These were forward-looking expectations, not achieved outcomes; the filing warned that the pandemic could disrupt trials, sites, staff and collaborators.
- Funding outlook: Inovio expected to continue relying on outside financing, collaborations and grants, and stated it might never achieve positive cash flow or profitability. No formal revenue or earnings guidance is provided.
- Key risks: Clinical-trial failure or delay, regulatory uncertainty, dependence on external funding and milestone payments, revenue concentration, competition, product manufacturing and third-party contractor risks, intellectual-property challenges, and potential dilution or cash demands from convertible debt. The company relied on VGXI, a GeneOne subsidiary, for DNA-plasmid supply. It also identified COVID-19-related disruption risk.
- Other disclosures: The company reported no material pending legal proceedings. Its independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; management also concluded controls were effective at year-end.
Important facts for investors to verify
- Current cash, investment balances, cash burn and runway, incorporating the $208.2 million ATM proceeds raised after year-end and subsequent expenditures.
- Updated share count and dilution from the 43.1 million post-year-end shares sold, plus potential conversion of notes and bonds.
- Convertible debt terms and potential cash settlement, repurchase obligations, conversion-price resets, derivative valuation and effective interest costs.
- REVEAL 1 and REVEAL 2 enrollment, readouts, endpoint results and regulatory plans for VGX-3100; distinguish trial results from management expectations.
- Whether reported interim GBM results are confirmed in later follow-up and whether other pipeline programs advance, pause or change.
- Actual regulatory, clinical and manufacturing progress for INO-4800 versus the filing’s early-2020 targets, and any effect of pandemic-related disruptions.
- Revenue dependence on AstraZeneca and the timing and conditions of collaboration, grant and milestone funding.